Synthon Hispania, S.L., Spain (manufacturing (full cycle), including batch release)

The drug is prescribed to women in the postmenopausal period for the treatment of advanced breast cancer (with positive hormone receptor status), as well as for the adjuvant treatment of early-stage invasive breast cancer.

Dosage form: tablets, film-coated

ATC: L02BG03